Eric Shaff Biography and Net Worth

https://ir.pragroup.com/board-of-directors?item=14 of Seres Therapeutics

Eric Shaff has over 15 years of experience working in leadership roles in biotechnology finance, corporate development and capital markets. Prior to Seres, he was Vice President, Corporate Finance at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products with annual revenue greater than $2 billion. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance as well as corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer, and worked in investment banking for Broadview International (now Jefferies LLC). Eric holds a B.A. from the University of Pennsylvania in political science and economics, and a M.B.A. with a concentration in finance from the Johnson Graduate School of Management at Cornell University.

What is Eric D. Shaff's net worth?: The estimated net worth of Eric D. Shaff is at least $69,319.22 as of February 18th, 2025. Mr. Shaff owns 9,601 shares of Seres Therapeutics stock worth more than $69,319 as of June 1st. This net worth approximation does not reflect any other investments that Mr. Shaff may own. Additionally, Mr. Shaff receives an annual salary of $1,020,000.00 as https://ir.pragroup.com/board-of-directors?item=14 at Seres Therapeutics. Learn More about Eric D. Shaff's net worth.
How old is Eric D. Shaff?: Mr. Shaff is currently 48 years old. There are 6 older executives and no younger executives at Seres Therapeutics. Learn More on Eric D. Shaff's age.
What is Eric D. Shaff's salary?: As the https://ir.pragroup.com/board-of-directors?item=14 of Seres Therapeutics, Inc., Mr. Shaff earns $1,020,000.00 per year. Learn More on Eric D. Shaff's salary.
How do I contact Eric D. Shaff?: The corporate mailing address for Mr. Shaff and other Seres Therapeutics executives is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. Seres Therapeutics can also be reached via phone at (617) 945-9626 and via email at ctanzi@serestherapeutics.com. Learn More on Eric D. Shaff's contact information.
Has Eric D. Shaff been buying or selling shares of Seres Therapeutics?: Eric D. Shaff has not been actively trading shares of Seres Therapeutics during the past quarter. Most recently, Eric D. Shaff sold 636 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $16.20, for a transaction totalling $10,303.20. Following the completion of the sale, the chief executive officer now directly owns 9,601 shares of the company's stock, valued at $155,536.20. Learn More on Eric D. Shaff's trading history.
Who are Seres Therapeutics' active insiders?: Seres Therapeutics' insider roster includes Thomas DesRosier (EVP), Matthew Henn (Insider), Eric Shaff (https://ir.pragroup.com/board-of-directors?item=14), and Teresa Young (Executive Vice President, Chief Commercial and Strategy Officer). Learn More on Seres Therapeutics' active insiders.
Are insiders buying or selling shares of Seres Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 13 times. They sold a total of 3,569 shares worth more than $61,314.60. The most recent insider tranaction occured on February, 18th when insider Matthew R Henn sold 197 shares worth more than $3,191.40. Insiders at Seres Therapeutics own 4.7% of the company. Learn More about insider trades at Seres Therapeutics.
Information on this page was last updated on 2/18/2025.

Eric D. Shaff Insider Trading History at Seres Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/18/2025	Sell	636	$16.20	$10,303.20	9,601
11/18/2024	Sell	125	$10.80	$1,350.00	8,519
10/28/2024	Sell	437	$13.80	$6,030.60	8,254
8/16/2024	Sell	125	$16.80	$2,100.00	7,299
5/15/2024	Sell	121	$18.80	$2,274.80	7,034
2/16/2024	Sell	577	$21.60	$12,463.20	6,766
10/30/2023	Sell	427	$27.00	$11,529.00	5,781
1/28/2019	Sell	218	$115.00	$25,070.00	861
6/30/2016	Sell	226	$590.80	$133,520.80	226
6/28/2016	Sell	250	$565.60	$141,400.00	166
4/4/2016	Sell	328	$577.00	$189,256.00	328
3/31/2016	Sell	383	$526.00	$201,458.00	383
3/28/2016	Sell	273	$481.40	$131,422.20	273

Eric D. Shaff Buying and Selling Activity at Seres Therapeutics

Seres Therapeutics Company Overview

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $7.22

$6.84

$7.33

50 Day Range

MA: $9.57

$6.77

$15.10

2 Week Range

Now: $7.22

$6.53

$30.60

Volume

88,626 shs

Average Volume

146,299 shs

Market Capitalization

$63.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.89

Eric Shaff Biography and Net Worth

What is Eric D. Shaff's net worth?

How old is Eric D. Shaff?

What is Eric D. Shaff's salary?

How do I contact Eric D. Shaff?

Has Eric D. Shaff been buying or selling shares of Seres Therapeutics?

Who are Seres Therapeutics' active insiders?

Are insiders buying or selling shares of Seres Therapeutics?